List of Hycamtin drug patents

Hycamtin is owned by Novartis.

Hycamtin contains Topotecan Hydrochloride.

Hycamtin has a total of 1 drug patent out of which 0 drug patents have expired.

Hycamtin was authorised for market use on 11 October, 2007.

Hycamtin is available in capsule;oral dosage forms.

The generics of Hycamtin are possible to be released after 10 December, 2024.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8158645 NOVARTIS Compound, corresponding compositions, preparation and/or treatment methods
Dec, 2024

(1 year, 6 months from now)

Do you want to check out HYCAMTIN patents from before 2022?

Drugs and Companies using TOPOTECAN HYDROCHLORIDE ingredient

Market Authorisation Date: 11 October, 2007

Treatment: NA

Dosage: CAPSULE;ORAL

More Information on Dosage

HYCAMTIN family patents

6

United States

1

Canada

1

Iceland

1

Argentina

1

Brazil

1

China

1

Australia

1

South Africa

1

Israel

1

Russia

1

Japan

1

Morocco

1

Norway

1

Taiwan

1

Korea, Republic of

1

European Union

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in